Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD16-MUC1 bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Benhealth Biopharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CD16-MUC1 bispecific antibody is a preclinical-stage therapeutic candidate being developed by Benhealth Biopharmaceutical. It is designed as a bispecific immune cell engager that simultaneously binds to CD16 (FcγRIII) on effector cells, such as natural killer (NK) cells and macrophages, and Mucin 1 (MUC1), a glycoprotein overexpressed on the surface of various tumor cells. By facilitating the proximity between immune effector cells and MUC1-positive cancer cells, the antibody triggers antibody-dependent cellular cytotoxicity (ADCC) and other immune-mediated killing mechanisms. This approach is intended for the treatment of MUC1-expressing solid tumors, including breast, lung, and pancreatic cancers.
- Other names
- CD16 x MUC1 bispecific antibodyCD-16 x MUC1 bispecific antibodyCD 16 x MUC1 bispecific antibodyMUC1 x CD16 bispecific antibodyMUC-1 x CD16 bispecific antibodyMUC 1 x CD16 bispecific antibodyanti-CD16 x anti-MUC1 bispecific antibodyanti-CD-16 x anti-MUC1 bispecific antibodyanti-CD 16 x anti-MUC1 bispecific antibody
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)MUC1 (Mucin-1 Antigen)FCGR3B (Fc gamma receptor III)
Beyond the preview
Go deeper on CD16-MUC1 bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD16-MUC1 bispecific antibody.